Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs

Piotr Podwalski; Jerzy Samochowiec

doi:10.5114/fpn.2022.117700

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

Otwarty dostęp

1/2022
vol. 38

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł przeglądowy

Nomenklatura oparta na Neuronauce – zmiana paradygmatu klasyfikacji leków psychiatrycznych

Piotr Podwalski

¹

,

Jerzy Samochowiec

¹

Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland;
Katedra i Klinika Psychiatrii, Pomorski Uniwersytet Medyczny, Szczecin, Polska

Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 35–47

DOI: https://doi.org/10.5114/fpn.2022.117700

Data publikacji online: 2022/08/02

Plik artykułu:

- 03R_IPiN_FARM_2022-1C.pdf [0.91 MB]

Pobierz cytowanie

Metryki PlumX:

1. Blier P, Oquendo MA, Kupfer DJ. Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology 2017; 42(10), 1927-1928; https://doi.org/10.1038/npp.2017.33.

2. Carlsson A. A Paradigm Shift in Brain Research. Science 2001; 294(5544), 1021-1024; https://doi.org/10.1126/science.1066969.

3. Gorwood P, Frangou S, Heun R. Editorial: Neuroscience-based Nomenclature (NbN) replaces the current label of psychotropic medications in European Psychiatry. European Psychiatry 2017; 40 (July 2016): 123; https://doi.org/10.1016/j.eurpsy.2016.07.009.

4. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 2000; 57(5), 503-509. https://doi.org/10.1001/archpsyc.57.5.503.

5. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Canadian Journal of Psychiatry 2016; 61(9), 540-560; https://doi.org/10.1177/0706743716659417.

6. Kickbusch I, Piselli D, Agrawal A, Balicer R, Banner O, Adelhardt M et al. The Lancet and Financial Times Commission on governing health futures 2030: growing up in a digital world. The Lancet 2021; 398(10312), 1727-1776; https://doi.org/10.1016/S0140-6736(21)01824-9.

7. Prieto E, Micó JA, Meana JJ, Majadas S. Neurobiological basis of quetiapine’s antidepressant effect in the bipolar disorder. Actas Espanolas de Psiquiatria 2010; 38(1), 22-32.

8. Rønning M, Blix HS, Harbø BT, Strøm HS. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – Are drug utilisation data comparable? European Journal of Clinical Pharmacology 2000; 56 (9-10), 723–727; https://doi.org/10.1007/s002280000200.

9. Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from ‘major tranquilizers’ to Neuroscience-based-Nomenclature. Psychological Medicine 2021; 51(3), 522-524; https://doi.org/10.1017/S0033291719003957.

10. Tang SW, Tang WH, Leonard BE. Herbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature. World Journal of Biological Psychiatry 2019; 20(8), 586-604; https://doi.org/10.1080/15622975.2017.1346279.

11. Uchida H. Neuroscience-based Nomenclature: What is it, why is it needed, and what comes next? Psychiatry and Clinical Neurosciences 2018; 72(2), 50-51; https://doi.org/10.1111/pcn.12615.

12. Unterecker S. Compliance and Psychoeducation. In: NeuroPsychopharmacotherapy. Springer International Publishing 2020; pp. 1-9; https://doi.org/10.1007/978-3-319-56015-1_6-1.

13. Urban S, Raś P. Treatment of anxiety disorders. Dialogues in Clinical Neuroscience 2017; 19(2), 93-107; https://doi.org/10.31887/DCNS.2017.19.2/bbandelow.

14. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC classification and DDD assignment; 2000.

15. Wilson S. Naming the drugs we use: neuroscience-based nomenclature, a helpful innovation. Therapeutic Advances in Psychopharmacology 2018; 8(6), 171-172; https://doi.org/10.1177/2045125318762065.

16. Zohar J, Kasper S. Neuroscience-based Nomenclature (NbN): A call for action. World Journal of Biological Psychiatry 2016; 17(5), 318-320; https://doi.org/10.1080/15622975.2016.1193626.

17. Zohar J, Stahl S, Moller H-J, Blier P, Kupfer D, Yamawaki S et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology 2015; 25(12), 2318-2325; https://doi.org/10.1016/j.euroneuro.2015.08.019.

Nomenklatura oparta na Neuronauce – zmiana paradygmatu klasyfikacji leków psychiatrycznych

Piotr Podwalski 1 , Jerzy Samochowiec 1

Piotr Podwalski

¹

,

Jerzy Samochowiec

¹